{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:30:07Z","timestamp":1782487807889,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301469"],"award-info":[{"award-number":["82301469"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171777"],"award-info":[{"award-number":["82171777"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["20JCJQJC00280"],"award-info":[{"award-number":["20JCJQJC00280"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tianjin Public Health Science and Technology Major Project","award":["24ZXGZSY00030"],"award-info":[{"award-number":["24ZXGZSY00030"]}]},{"name":"Tianjin Health Research Project","award":["TJSQNYXXR-D2-120"],"award-info":[{"award-number":["TJSQNYXXR-D2-120"]}]},{"name":"Tianjin Health Research Project","award":["TJWJ2024RC001"],"award-info":[{"award-number":["TJWJ2024RC001"]}]},{"name":"Leading Talent of Changzhou \u201cThe 14th Five-Year Plan\u201d High-Level Health Talents Training Project","award":["2024CZLJ003"],"award-info":[{"award-number":["2024CZLJ003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00415-025-13408-2","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:38:09Z","timestamp":1758886689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ofatumumab treatment in patients with neuromyelitis optica spectrum disorder: a retrospective multicenter cohort study"],"prefix":"10.1007","volume":"272","author":[{"given":"Xiaoxia","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuegan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daishi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuju","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shougang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youming","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihou","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkai","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiyuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Dong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0659-4597","authenticated-orcid":false,"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"13408_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMOD (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"13408_CR2","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","volume":"20","author":"A Uzawa","year":"2024","unstructured":"Uzawa A, Oertel FC, Mori M, Paul F, Kuwabara S (2024) NMOSD and MOGAD: an evolving disease spectrum. Nat Rev Neurol 20:602\u2013619. https:\/\/doi.org\/10.1038\/s41582-024-01014-1","journal-title":"Nat Rev Neurol"},{"key":"13408_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ana.20770","volume":"59","author":"BG Weinshenker","year":"2006","unstructured":"Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59:566\u2013569. https:\/\/doi.org\/10.1002\/ana.20770","journal-title":"Ann Neurol"},{"key":"13408_CR4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000104","volume":"2","author":"JL Bennett","year":"2015","unstructured":"Bennett JL, O\u2019Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, von Budingen HC, Stuve O, Yeaman MR, Smith TJ, Stadelmann C (2015) B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2:e104. https:\/\/doi.org\/10.1212\/NXI.0000000000000104","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13408_CR5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1093\/brain\/awz106","volume":"142","author":"E Cotzomi","year":"2019","unstructured":"Cotzomi E, Stathopoulos P, Lee CS, Ritchie AM, Soltys JN, Delmotte FR, Oe T, Sng J, Jiang R, Ma AK, Vander Heiden JA, Kleinstein SH, Levy M, Bennett JL, Meffre E, O\u2019Connor KC (2019) Early B-cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain 142:1598\u20131615. https:\/\/doi.org\/10.1093\/brain\/awz106","journal-title":"Brain"},{"key":"13408_CR6","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F (2017) Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 264:2003\u20132009. https:\/\/doi.org\/10.1007\/s00415-017-8590-0","journal-title":"J Neurol"},{"key":"13408_CR7","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R (2016) Efficacy and safety of Rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 73:1342\u20131348. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1637","journal-title":"JAMA Neurol"},{"key":"13408_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H (2020) Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19:298\u2013306. https:\/\/doi.org\/10.1016\/S1474-4422(20)30066-1","journal-title":"Lancet Neurol"},{"key":"13408_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200211","volume":"11","author":"A Langer-Gould","year":"2024","unstructured":"Langer-Gould A, Li BH, Smith JB, Xu S (2024) Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections. Neurol Neuroimmunol Neuroinflamm 11:e200211. https:\/\/doi.org\/10.1212\/NXI.0000000000200211","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13408_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201260","volume":"99","author":"P Barreras","year":"2022","unstructured":"Barreras P, Vasileiou ES, Filippatou AG, Fitzgerald KC, Levy M, Pardo CA, Newsome SD, Mowry EM, Calabresi PA, Sotirchos ES (2022) Long-term effectiveness and safety of Rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease. Neurology 99:e2504\u2013e2516. https:\/\/doi.org\/10.1212\/WNL.0000000000201260","journal-title":"Neurology"},{"key":"13408_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102727","volume":"20","author":"O Mirmosayyeb","year":"2021","unstructured":"Mirmosayyeb O, Shaygannejad V, Barzegar M, Nehzat N, Ghajarzadeh M (2021) Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): a systematic review and meta-analysis. Autoimmun Rev 20:102727. https:\/\/doi.org\/10.1016\/j.autrev.2020.102727","journal-title":"Autoimmun Rev"},{"key":"13408_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/jnnp-2022-330086","volume":"94","author":"G Spagni","year":"2023","unstructured":"Spagni G, Sun B, Monte G, Sechi E, Iorio R, Evoli A, Damato V (2023) Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 94:62\u201369. https:\/\/doi.org\/10.1136\/jnnp-2022-330086","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13408_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77:184\u2013191. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3365","journal-title":"JAMA Neurol"},{"key":"13408_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"SH Kim","year":"2015","unstructured":"Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, Yun S, Joo J, Kim HJ (2015) Treatment outcomes with Rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to Rituximab. JAMA Neurol 72:989\u2013995. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1276","journal-title":"JAMA Neurol"},{"key":"13408_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","volume":"316","author":"T Li","year":"2018","unstructured":"Li T, Zhang LJ, Zhang QX, Yang CS, Zhang C, Li YJ, Shi FD, Yang L (2018) Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab. J Neuroimmunol 316:107\u2013111. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.12.021","journal-title":"J Neuroimmunol"},{"key":"13408_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Haring DA, Ramanathan K, Merschhemke M, Kappos L, Groups AIT (2020) Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383:546\u2013557. https:\/\/doi.org\/10.1056\/NEJMoa1917246","journal-title":"N Engl J Med"},{"key":"13408_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.scitotenv.2003.08.024","volume":"327","author":"CG Flocco","year":"2004","unstructured":"Flocco CG, Carranza MP, Carvajal LG, Loewy RM, Pechen de D\u2019Angelo AM, Giulietti AM (2004) Removal of azinphos methyl by alfalfa plants (Medicago sativa L.) in a soil-free system. Sci Total Environ 327:31\u201339. https:\/\/doi.org\/10.1016\/j.scitotenv.2003.08.024","journal-title":"Sci Total Environ"},{"key":"13408_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Schafer W, Georges G, Schwaiger M, Mossner E, Hopfner KP, Umana P, Niederfellner G (2013) Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 5:22\u201333. https:\/\/doi.org\/10.4161\/mabs.22771","journal-title":"MAbs"},{"key":"13408_CR19","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s40120-023-00518-0","volume":"12","author":"SL Hauser","year":"2023","unstructured":"Hauser SL, Kappos L, Bar-Or A, Wiendl H, Paling D, Williams M, Gold R, Chan A, Milo R, Das Gupta A, Karlsson G, Sullivan R, Graham G, Merschhemke M, Haring DA, Vermersch P (2023) The development of ofatumumab, a fully human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment. Neurol Ther 12:1491\u20131515. https:\/\/doi.org\/10.1007\/s40120-023-00518-0","journal-title":"Neurol Ther"},{"key":"13408_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01340","volume":"10","author":"D Theil","year":"2019","unstructured":"Theil D, Smith P, Huck C, Gilbart Y, Kakarieka A, Leppert D, Rauld C, Schmid C, Baumgartner R, Stuber N, Cordoba F, Dubost V, Darribat K, Jivkov M, Frieauff W, Kneuer R, Stoeckli M, Reinker S, Mansfield K, Carballido JM, Couttet P, Weckbecker G (2019) Imaging mass cytometry and single-cell genomics reveal differential depletion and repletion of B-cell populations following Ofatumumab treatment in Cynomolgus monkeys. Front Immunol 10:1340. https:\/\/doi.org\/10.3389\/fimmu.2019.01340","journal-title":"Front Immunol"},{"key":"13408_CR21","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1172\/JCI125740","volume":"129","author":"L Kahari","year":"2019","unstructured":"Kahari L, Fair-Makela R, Auvinen K, Rantakari P, Jalkanen S, Ivaska J, Salmi M (2019) Transcytosis route mediates rapid delivery of intact antibodies to draining lymph nodes. J Clin Investig 129:3086\u20133102. https:\/\/doi.org\/10.1172\/JCI125740","journal-title":"J Clin Investig"},{"key":"13408_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ana.27143","volume":"97","author":"SG Meuth","year":"2025","unstructured":"Meuth SG, Wolff S, Muck A, Willison A, Kleinschnitz K, Rauber S, Pawlitzki M, Konen FF, Skripuletz T, Grothe M, Ruck T, Huttner HB, Kleinschnitz C, Bopp T, Pul R, Cree BAC, Hartung HP, Mollenhoff K, Pfeuffer S (2025) Different treatment outcomes of multiple sclerosis patients receiving ocrelizumab or ofatumumab. Ann Neurol 97:583\u2013595. https:\/\/doi.org\/10.1002\/ana.27143","journal-title":"Ann Neurol"},{"key":"13408_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.814064","volume":"13","author":"JB Torres","year":"2022","unstructured":"Torres JB, Roodselaar J, Sealey M, Ziehn M, Bigaud M, Kneuer R, Leppert D, Weckbecker G, Cornelissen B, Anthony DC (2022) Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol 13:814064. https:\/\/doi.org\/10.3389\/fimmu.2022.814064","journal-title":"Front Immunol"},{"key":"13408_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11481-019-09872-z","volume":"14","author":"C Huck","year":"2019","unstructured":"Huck C, Leppert D, Wegert V, Schmid C, Dunn R, Weckbecker G, Smith PA (2019) Low-dose subcutaneous anti-CD20 treatment depletes disease relevant B cell subsets and attenuates neuroinflammation. J Neuroimmune Pharmacol 14:709\u2013719. https:\/\/doi.org\/10.1007\/s11481-019-09872-z","journal-title":"J Neuroimmune Pharmacol"},{"key":"13408_CR25","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000683","author":"E Maillart","year":"2020","unstructured":"Maillart E, Renaldo F, Papeix C, Deiva K, Bonheur J, Kwon T, Boespflug-Tanguy O, Germanaud D, Marignier R (2020) Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000683","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13408_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1047992","volume":"13","author":"W Zhang","year":"2022","unstructured":"Zhang W, Jiao Y, Jiao J, Jin M, Peng D (2022) Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: a case report. Front Immunol 13:1047992. https:\/\/doi.org\/10.3389\/fimmu.2022.1047992","journal-title":"Front Immunol"},{"key":"13408_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578035","volume":"376","author":"B Gou","year":"2023","unstructured":"Gou B, Yang P, Feng J, Li Y, Huang G, Shi J, Wen L, Guo X, Zheng P, Yu G (2023) The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab. J Neuroimmunol 376:578035. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578035","journal-title":"J Neuroimmunol"},{"key":"13408_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1208017","volume":"14","author":"Y Zhan","year":"2023","unstructured":"Zhan Y, Zhao M, Li X, Ouyang H, Du C, Chen G, Lou Z, Chen H, Zhao Y, Xu H (2023) A meaningful exploration of ofatumumab in refractory NMOSD: a case report. Front Immunol 14:1208017. https:\/\/doi.org\/10.3389\/fimmu.2023.1208017","journal-title":"Front Immunol"},{"key":"13408_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005516","volume":"90","author":"A Bar-Or","year":"2018","unstructured":"Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE, Sorensen PS (2018) Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology 90:e1805\u2013e1814. https:\/\/doi.org\/10.1212\/WNL.0000000000005516","journal-title":"Neurology"},{"key":"13408_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000136645","volume":"31","author":"JF Kurtzke","year":"2008","unstructured":"Kurtzke JF (2008) Historical and clinical perspectives of the expanded disability status scale. Neuroepidemiology 31:1\u20139. https:\/\/doi.org\/10.1159\/000136645","journal-title":"Neuroepidemiology"},{"key":"13408_CR31","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70:1110\u20131117. https:\/\/doi.org\/10.1001\/jamaneurol.2013.3071","journal-title":"JAMA Neurol"},{"key":"13408_CR32","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1177\/1352458511404586","volume":"17","author":"GS Bedi","year":"2011","unstructured":"Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA (2011) Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler J 17:1225\u20131230. https:\/\/doi.org\/10.1177\/1352458511404586","journal-title":"Mult Scler J"},{"key":"13408_CR33","doi-asserted-by":"publisher","first-page":"7078","DOI":"10.1128\/mcb.14.11.7078-7085.1994","volume":"14","author":"JP Medema","year":"1994","unstructured":"Medema JP, Sark MW, Backendorf C, Bos JL (1994) Calcium inhibits epidermal growth factor-induced activation of p21ras in human primary keratinocytes. Mol Cell Biol 14:7078\u20137085. https:\/\/doi.org\/10.1128\/mcb.14.11.7078-7085.1994","journal-title":"Mol Cell Biol"},{"key":"13408_CR34","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1212\/01.wnl.0000049912.02954.2c","volume":"60","author":"DM Wingerchuk","year":"2003","unstructured":"Wingerchuk DM, Weinshenker BG (2003) Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 60:848\u2013853. https:\/\/doi.org\/10.1212\/01.wnl.0000049912.02954.2c","journal-title":"Neurology"},{"key":"13408_CR35","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s11136-020-02707-y","volume":"30","author":"CE Schwartz","year":"2021","unstructured":"Schwartz CE, Stark RB, Stucky BD (2021) Response-shift effects in neuromyelitis optica spectrum disorder: a secondary analysis of clinical trial data. Qual Life Res 30:1267\u20131282. https:\/\/doi.org\/10.1007\/s11136-020-02707-y","journal-title":"Qual Life Res"},{"key":"13408_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ana.26722","volume":"94","author":"M Majed","year":"2023","unstructured":"Majed M, Valencia Sanchez C, Bennett JL, Fryer J, Mulligan MD, Redenbaugh V, McKeon A, Mills JR, Wingerchuk DM, Lennon VA, Weinshenker B, Chen JJ, Flanagan EP, Pittock SJ, Kunchok A (2023) Alterations in Aquaporin-4-IgG serostatus in 986 patients: a laboratory-based longitudinal analysis. Ann Neurol 94:727\u2013735. https:\/\/doi.org\/10.1002\/ana.26722","journal-title":"Ann Neurol"},{"key":"13408_CR37","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11910-023-01287-x","volume":"23","author":"HYF Yong","year":"2023","unstructured":"Yong HYF, Burton JM (2023) A clinical approach to existing and emerging therapeutics in neuromyelitis optica spectrum disorder. Curr Neurol Neurosci Rep 23:489\u2013506. https:\/\/doi.org\/10.1007\/s11910-023-01287-x","journal-title":"Curr Neurol Neurosci Rep"},{"key":"13408_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106314","volume":"95","author":"C Wang","year":"2025","unstructured":"Wang C, Liu J, Gao X, Shen Y, Pan J, Yang S, Fan M, Jia D, Zhang C (2025) Effectiveness and safety of glucocorticoids bridging rituximab in neuromyelitis spectrum disorder. Mult Scler Relat Disord 95:106314. https:\/\/doi.org\/10.1016\/j.msard.2025.106314","journal-title":"Mult Scler Relat Disord"},{"key":"13408_CR39","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001070","author":"C Zhang","year":"2021","unstructured":"Zhang C, Zhang TX, Liu Y, Jia D, Zeng P, Du C, Yuan M, Liu Q, Wang Y, Shi FD (2021) B-cell compartmental features and molecular basis for therapy in autoimmune disease. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001070","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13408_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578167","volume":"382","author":"Z Huang","year":"2023","unstructured":"Huang Z, Liu Y, An X, Zhang C, Zhang TX, Li H, Feng B, Li YY, Zhang C (2023) Rituximab induces a transient fluctuation of peripheral and follicular helper T cells in neuromyelitis optica spectrum disorder. J Neuroimmunol 382:578167. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578167","journal-title":"J Neuroimmunol"},{"key":"13408_CR41","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000061","volume":"2","author":"JS Perumal","year":"2015","unstructured":"Perumal JS, Kister I, Howard J, Herbert J (2015) Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2:e61. https:\/\/doi.org\/10.1212\/NXI.0000000000000061","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13408_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103143","volume":"54","author":"B Shi","year":"2021","unstructured":"Shi B, Zhao M, Qiao L, Huang F, Zhou S, Wei Y, Wang J, Wang N (2021) Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 54:103143. https:\/\/doi.org\/10.1016\/j.msard.2021.103143","journal-title":"Mult Scler Relat Disord"},{"key":"13408_CR43","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","volume":"18","author":"I Nakashima","year":"2011","unstructured":"Nakashima I, Takahashi T, Cree BA, Kim HJ, Suzuki C, Genain CP, Vincent T, Fujihara K, Itoyama Y, Bar-Or A (2011) Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci 18:997\u2013998. https:\/\/doi.org\/10.1016\/j.jocn.2010.12.011","journal-title":"J Clin Neurosci"},{"key":"13408_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jneuroim.2015.11.006","volume":"290","author":"MA Maurer","year":"2016","unstructured":"Maurer MA, Tuller F, Gredler V, Berger T, Lutterotti A, Lunemann JD, Reindl M (2016) Rituximab induces clonal expansion of IgG memory B cells in patients with inflammatory central nervous system demyelination. J Neuroimmunol 290:49\u201353. https:\/\/doi.org\/10.1016\/j.jneuroim.2015.11.006","journal-title":"J Neuroimmunol"},{"key":"13408_CR45","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 394:1352\u20131363. https:\/\/doi.org\/10.1016\/S0140-6736(19)31817-3","journal-title":"Lancet"},{"key":"13408_CR46","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/13524585211047223","volume":"28","author":"M Rensel","year":"2022","unstructured":"Rensel M, Zabeti A, Mealy MA, Cimbora D, She D, Drappa J, Katz E (2022) Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for \u2a7e4 years in the N-MOmentum trial. Mult Scler J 28:925\u2013932. https:\/\/doi.org\/10.1177\/13524585211047223","journal-title":"Mult Scler J"},{"key":"13408_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-021-00667-3","volume":"23","author":"M Tugizova","year":"2021","unstructured":"Tugizova M, Vlahovic L, Tomczak A, Wetzel NS, Han MH (2021) New therapeutic landscape in neuromyelitis optica. Curr Treat Options Neurol 23:13. https:\/\/doi.org\/10.1007\/s11940-021-00667-3","journal-title":"Curr Treat Options Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13408-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13408-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13408-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:02:25Z","timestamp":1761699745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13408-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["13408"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13408-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study protocol was approved by the review board of Tianjin Medical University General Hospital Review Board (IRB2024-YX-267-01) and written informed consent was obtained from all patients or their families.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"655"}}